Multi-institutional re-evaluation of prognostic factors in chromophobe renal cell carcinoma: proposal of a novel two-tiered grading scheme.


Journal

Virchows Archiv : an international journal of pathology
ISSN: 1432-2307
Titre abrégé: Virchows Arch
Pays: Germany
ID NLM: 9423843

Informations de publication

Date de publication:
Mar 2020
Historique:
received: 10 10 2019
accepted: 25 10 2019
revised: 10 10 2019
pubmed: 25 11 2019
medline: 31 3 2020
entrez: 25 11 2019
Statut: ppublish

Résumé

A histological grading system of chromophobe renal cell carcinoma (chRCC) is highly desirable to identify approximately 5-10% of tumors at risk for progression. Validation studies failed to demonstrate a correlation between the four-tiered WHO/ISUP grade and outcome. Previous proposals with three-tiered chromophobe grading systems could not be validated. In this study, the presence of sarcomatoid differentiation, necrosis, and mitosis was analyzed in a Swiss cohort (n = 42), an Italian cohort (n = 103), a German cohort (n = 54), a Japanese cohort (n = 119), and The Cancer Genome Atlas cohort (n = 64). All 3 histological parameters were significantly associated with shorter time to tumor progression and overall survival in univariate analysis. Interobserver variability for identification of these parameters was measured by Krippendorff's alpha coefficient and showed high concordance for the identification of sarcomatoid differentiation and tumor necrosis, but only low to medium concordance for the identification of mitosis. Therefore, we tested a two-tiered tumor grading system (low versus high grade) based only on the presence of sarcomatoid differentiation and/or necrosis finding in the combined cohorts (n = 382). pT stage, patient's age (> 65 vs ≤ 65), lymph node and/or distant metastasis, and the two-tiered grading system (low versus high grade) were significantly associated with overall survival and were independent prognostic parameters in multivariate analysis (Cox proportional hazard). This multi-institutional evaluation of prognostic parameters suggests tumor necrosis and sarcomatoid differentiation as reproducible components of a two-tiered chromophobe tumor grading system.

Identifiants

pubmed: 31760491
doi: 10.1007/s00428-019-02710-w
pii: 10.1007/s00428-019-02710-w
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

409-418

Commentaires et corrections

Type : CommentIn
Type : ErratumIn

Références

Davis CF, Ricketts CJ, Wang M et al (2014) The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell 26:319–330
doi: 10.1016/j.ccr.2014.07.014
Amin MB, Paner GP, Alvarado-Cabrero I, Young AN, Stricker HJ, Lyles RH, Moch H (2008) Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases. Am J Surg Pathol 32:1822–1834
doi: 10.1097/PAS.0b013e3181831e68
Fuhrman SA, Lasky LC, Limas C (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6:655–663
doi: 10.1097/00000478-198210000-00007
Delahunt B, Cheville JC, Martignoni G, Humphrey PA, Magi-Galluzzi C, McKenney J, Egevad L, Algaba F, Moch H, Grignon DJ, Montironi R, Srigley JR, Members of the ISUP Renal Tumor Panel (2013) The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol 37:1490–1504
doi: 10.1097/PAS.0b013e318299f0fb
Paner G, Amin MB, Moch H, Störkel S. Chromophobe renal cell carcinoma. In: Moch H, Humphrey PA, Ulbright TM, Reuter VE, editors (2016) WHO Classification of Tumours of the Urinary System and Male Genital Organs 4th edition. International Agency for Research on Cancer: Lyon, pp 27-28
Delahunt B, Srigley JR, Judge MJ, Amin MB, Billis A, Camparo P, Evans AJ, Fleming S, Griffiths DF, Lopez-Beltran A, Martignoni G, Moch H, Nacey JN, Zhou M (2019) Data set for the reporting of carcinoma of renal tubular origin: recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology 74:377–390
doi: 10.1111/his.13754
Sika-Paotonu D, Bethwaite PB, McCredie MR, William Jordan T, Delahunt B (2006) Nucleolar grade but not Fuhrman grade is applicable to papillary renal cell carcinoma. Am J Surg Pathol 30:1091–1096
doi: 10.1097/01.pas.0000209833.69972.2b
Delahunt B, Sika-Paotonu D, Bethwaite PB et al (2011) Grading of clear cell renal cell carcinoma should be based on nucleolar prominence. Am J Surg Pathol 135:134–1139
Dagher J, Delahunt B, Rioux-Leclercq N, Egevad L, Srigley JR, Coughlin G, Dunglinson N, Gianduzzo T, Kua B, Malone G, Martin B, Preston J, Pokorny M, Wood S, Yaxley J, Samaratunga H (2017) Clear cell renal cell carcinoma: validation of World Health Organization/International Society of Urological Pathology grading. Histopathology 71:918–925
doi: 10.1111/his.13311
Delahunt B, Sika-Paotonu D, Bethwaite PB et al (2007) Fuhrman grading is not appropriate for chromophobe renal cell carcinoma. Am J Surg Pathol 31:957–960
doi: 10.1097/01.pas.0000249446.28713.53
Tickoo SK, Amin MB (1998) Discriminant nuclear features of renal oncocytoma and chromophobe renal cell carcinoma. Analysis of their potential utility in the differential diagnosis. Am J Clin Pathol 110:782–787
doi: 10.1093/ajcp/110.6.782
Amin MB, Amin MB, Tamboli P, Javidan J, Stricker H, de-Peralta Venturina M, Deshpande A, Menon M (2002) Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol 26:281–291
doi: 10.1097/00000478-200203000-00001
Paner GP, Amin MB, Alvarado-Cabrero I et al (2010) A novel tumor grading scheme for chromophobe renal cell carcinoma: prognostic utility and comparison with Fuhrman nuclear grade. Am J Surg Pathol 34:1233–1240
doi: 10.1097/PAS.0b013e3181e96f2a
Lohse CM, Blute ML, Zincke H, Weaver AL, Cheville JC (2002) Comparison of standardized and nonstandardized nuclear grade of renal cell carcinoma to predict outcome among 2,042 patients. Am J Clin Pathol 118:877–886
doi: 10.1309/VLV6-BRTR-HY5B-H485
Delahunt B, Eble JN, Egevad L, Samaratunga H (2019) Grading of renal cell carcinoma. Histopathology 74:4–17
doi: 10.1111/his.13735
Griffiths IH, Thackray AC (1949) Parenchymal carcinoma of the kidney. Br J Urol 21:128–151
doi: 10.1111/j.1464-410X.1949.tb10761.x
Ohashi R, Schraml P, Angori S et al (2019) Classic chromophobe renal cell carcinoma incur a larger number of chromosomal losses than seen in the eosinophilic subtype. Cancers 11:1492
doi: 10.3390/cancers11101492
Ohe C, Kuroda N, Matsuura K et al (2014) Chromophobe renal cell carcinoma with neuroendocrine differentiation/morphology: a clinicopathological and genetic study of three cases. Hum Pathol Case Reports 1:31–39
doi: 10.1016/j.ehpc.2014.08.003
Mokhtar GA, Al-Zahrani R (2015) Chromophobe renal cell carcinoma of the kidney with neuroendocrine differentiation: a case report with review of literature. Urol Ann 7:383–386
pubmed: 26229333 pmcid: 4518382
Peckova K, Martinek P, Ohe C, Kuroda N, Bulimbasic S, Condom Mundo E, Perez Montiel D, Lopez JI, Daum O, Rotterova P, Kokoskova B, Dubova M, Pivovarcikova K, Bauleth K, Grossmann P, Hora M, Kalusova K, Davidson W, Slouka D, Miroslav S, Buzrla P, Hynek M, Michal M, Hes O (2015) Chromophobe renal cell carcinoma with neuroendocrine and neuroendocrine-like features. Morphologic, immunohistochemical, ultrastructural, and array comparative genomic hybridization analysis of 18 cases and review of the literature. Ann Diagn Pathol 19:261–268
doi: 10.1016/j.anndiagpath.2015.05.001
Brierley J, Gospodarowicz M, Wittekind C (2017) UICC TNM classification of malignant tumours, 8th edn. Wiley, Chichester
Akhtar M, Tulbah A, Kardar AH, Ali MA (1997) Sarcomatoid renal cell carcinoma: the chromophobe connection. Am J Surg Pathol 21:1188–1195
doi: 10.1097/00000478-199710000-00009
de Peralta-Venturina M, Moch H, Amin M, Tamboli P, Hailemariam S, Mihatsch M, Javidan J, Stricker H, Ro JY, Amin MB (2001) Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol 25:275–284
doi: 10.1097/00000478-200103000-00001
Hayes AF, Krippendorff K (2007) Answering the call for a standard reliability measure for coding data. Commun Methods Meas 1:77–89
doi: 10.1080/19312450709336664
Kanda Y (2013) Investigation of the freely-available easy-to-use software “EZR” (Easy R) for medical statistics. Bone Marrow Transplant 48:452–458
doi: 10.1038/bmt.2012.244
Firth D (1993) Bias reduction of maximum likelihood estimates. Biometrika 80:27–38
doi: 10.1093/biomet/80.1.27
Efron B, Tibshirani RJ (1986) Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. Stat Sci 1:54–77
doi: 10.1214/ss/1177013815
Matsuda Y, Yoshimura H, Ishiwata T, Sumiyoshi H, Matsushita A, Nakamura Y, Aida J, Uchida E, Takubo K, Arai T (2016) Mitotic index and multipolar mitosis in routine histologic sections as prognostic markers of pancreatic cancers: a clinicopathological study. Pancreatology 16:127–132
doi: 10.1016/j.pan.2015.10.005
Trpkov K, Williamson SR, Gao Y, Martinek P, Cheng L, Sangoi AR, Yilmaz A, Wang C, San Miguel Fraile P, Perez Montiel DM, Bulimbasić S, Rogala J, Hes O (2019) Low-grade oncocytic tumour of kidney (CD117-negative, cytokeratin 7-positive): a distinct entity? Histopathology 75:174–184
doi: 10.1111/his.13865
Przybycin CG, Cronin AM, Darvishian F, Gopalan A, al-Ahmadie HA, Fine SW, Chen YB, Bernstein M, Russo P, Reuter VE, Tickoo SK (2011) Chromophobe renal cell carcinoma: a clinicopathologic study of 203 tumors in 200 patients with primary resection at a single institution. Am J Surg Pathol 35:962–970
doi: 10.1097/PAS.0b013e31821a455d
Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML (2003) Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 27:612–624
doi: 10.1097/00000478-200305000-00005
Leibovich BC, Lohse CM, Cheville JC et al (2018) Predicting oncologic outcomes in renal cell carcinoma after surgery. Eur Urol 73:772–780
doi: 10.1016/j.eururo.2018.01.005
Volpe A, Novara G, Antonelli A et al (2012) Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series. BJU Int 110:76–83
doi: 10.1111/j.1464-410X.2011.10690.x
Casuscelli J, Weinhold N, Gundem G et al (2017) Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma. JCI Insight 2
Casuscelli J, Becerra MF, Seier K et al (2019) Chromophobe renal cell carcinoma: results from a large single-institution series. Clin Genitourin Cancer
Ged Y, Chen YB, Knezevic A, Casuscelli J, Redzematovic A, DiNatale R, Carlo MI, Lee CH, Feldman DR, Patil S, Hakimi AA, Russo P, Motzer RJ, Voss MH (2019) Metastatic chromophobe renal cell carcinoma: presence or absence of sarcomatoid differentiation determines clinical course and treatment outcomes. Clin Genitourin Cancer 17:e678–e688
doi: 10.1016/j.clgc.2019.03.018
Lakhani SR, Ellis IO, Schnitt SJ et al (2012) WHO classification of tumours of the breast. World Health Organization, Lyon
Rutkowski P, Bylina E, Wozniak A, Nowecki ZI, Osuch C, Matlok M, Switaj T, Michej W, Wroński M, Głuszek S, Kroc J, Nasierowska-Guttmejer A, Joensuu H (2011) Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - the impact of tumour rupture on patient outcomes. Eur J Surg Oncol 37:890–896
doi: 10.1016/j.ejso.2011.06.005
Lloyd RV, Osamura RY, Kloppel G et al (2017) WHO Classification of tumours of endocrine organs (World Health Organization Classification of Tumors), 4th edn. IARC Press, Lyons

Auteurs

Riuko Ohashi (R)

Histopathology Core Facility, Niigata University Faculty of Medicine, 1-757 Asahimachi-dori, Chuo-ku, Niigata, 951-8510, Japan.
Department of Pathology and Molecular Pathology, University and University Hospital Zurich, Schmelzbergstrasse 12, CH-8091, Zurich, Switzerland.
Division of Molecular and Diagnostic Pathology, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-dori, Chuo-ku, Niigata, 951-8510, Japan.

Guido Martignoni (G)

Department of Diagnostic and Public Health, University of Verona, Piazzale Ludovico Antonio Scuro 10, 37134, Verona, Italy.
Department of Pathology, Pederzoli Hospital, Via Monte Baldo 24, 37019, Peschiera del Garda, Italy.

Arndt Hartmann (A)

Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Krankenhausstrasse 8-10, 91054, Erlangen, Germany.

Anna Caliò (A)

Department of Diagnostic and Public Health, University of Verona, Piazzale Ludovico Antonio Scuro 10, 37134, Verona, Italy.

Diego Segala (D)

Department of Pathology, Pederzoli Hospital, Via Monte Baldo 24, 37019, Peschiera del Garda, Italy.

Christine Stöhr (C)

Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Krankenhausstrasse 8-10, 91054, Erlangen, Germany.

Sven Wach (S)

Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich Alexander-University Erlangen-Nürnberg, Krankenhausstrasse 12, 91054, Erlangen, Germany.

Franziska Erlmeier (F)

Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Krankenhausstrasse 8-10, 91054, Erlangen, Germany.
Institute of Pathology, Technical University Munich, Trogerstrasse 18, 81675, Munich, Germany.

Wilko Weichert (W)

Institute of Pathology, Technical University Munich, Trogerstrasse 18, 81675, Munich, Germany.

Michael Autenrieth (M)

Department of Urology, Technical University Munich, Klinikum rechts der Isar, Ismaninger Strasse 22, 81675, Munich, Germany.

Peter Schraml (P)

Department of Pathology and Molecular Pathology, University and University Hospital Zurich, Schmelzbergstrasse 12, CH-8091, Zurich, Switzerland.

Niels J Rupp (NJ)

Department of Pathology and Molecular Pathology, University and University Hospital Zurich, Schmelzbergstrasse 12, CH-8091, Zurich, Switzerland.

Chisato Ohe (C)

Department of Pathology and Laboratory Medicine, Kansai Medical University, 2-5-1 Shin-machi, Hirakata, 573-1010, Japan.

Yoshiro Otsuki (Y)

Department of Pathology, Seirei Hamamatsu General Hospital, 2-12-12 Sumiyoshi, Naka-ku, Hamamatsu, 430-8558, Japan.

Takashi Kawasaki (T)

Department of Pathology, Niigata Cancer Center Hospital, 2-15-3 Kawagishi-cho, Chuo-ku, Niigata, 951-8566, Japan.

Hiroshi Kobayashi (H)

Department of Pathology, Tachikawa General Hospital, 1-24 Asahioka, Nagaoka, 940-8621, Japan.

Kazuhiro Kobayashi (K)

Department of Pathology, Gifu University Hospital, 1-1 Yanagido, Gifu, 501-1194, Japan.

Tatsuhiko Miyazaki (T)

Department of Pathology, Gifu University Hospital, 1-1 Yanagido, Gifu, 501-1194, Japan.

Hiroyuki Shibuya (H)

Department of Pathology, Niigata City General Hospital, 463-7 Shumoku, Chuo-ku, Niigata, 950-1197, Japan.

Hiroyuki Usuda (H)

Department of Diagnostic Pathology, Nagaoka Red Cross Hospital, 2-297-1 Sensyu, Nagaoka, 940-2085, Japan.

Hajime Umezu (H)

Division of Pathology, Niigata University Medical & Dental Hospital, 1-754 Asahimachi-dori, Chuo-ku, Niigata, 951-8520, Japan.

Fumiyoshi Fujishima (F)

Department of Anatomic Pathology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.

Bungo Furusato (B)

Cancer Genomics Unit, Clinical Genomics Center, Nagasaki University Hospital, 1-7-1, Sakamoto, Nagasaki, 852-8501, Japan.
Department of Pathology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1, Sakamoto, Nagasaki, 852-8501, Japan.

Mitsumasa Osakabe (M)

Department of Molecular Diagnostic Pathology, School of Medicine, Iwate Medical University, 2-1-1, Idai-dori, Yahaba-cho, Shiwa-gun, Iwate, 028-3695, Japan.

Tamotsu Sugai (T)

Department of Molecular Diagnostic Pathology, School of Medicine, Iwate Medical University, 2-1-1, Idai-dori, Yahaba-cho, Shiwa-gun, Iwate, 028-3695, Japan.

Naoto Kuroda (N)

Department of Diagnostic Pathology, Kochi Red Cross Hospital, 1-4-63-11 hadaminamimachi, Kochi, Kochi, 780-8562, Japan.

Toyonori Tsuzuki (T)

Department of Surgical Pathology, Aichi Medical University Hospital, 1-1 Yazakokarimata, Nagakute, 480-1195, Japan.

Yoji Nagashima (Y)

Department of Surgical Pathology, Tokyo Women's Medical University Hospital, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan.

Yoichi Ajioka (Y)

Histopathology Core Facility, Niigata University Faculty of Medicine, 1-757 Asahimachi-dori, Chuo-ku, Niigata, 951-8510, Japan.
Division of Molecular and Diagnostic Pathology, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-dori, Chuo-ku, Niigata, 951-8510, Japan.

Holger Moch (H)

Department of Pathology and Molecular Pathology, University and University Hospital Zurich, Schmelzbergstrasse 12, CH-8091, Zurich, Switzerland. holger.moch@usz.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH